Contact
searchSearch
HMP Global
Login

Substance Use Disorder Topic Center

NYSAM 2026 Meeting Logo
Conference Coverage
NYSAM 2026 Spotlights Harm Reduction, Psychiatric Care in SUD Treatment
03/17/2026
Brionna Mendoza
At the 2026 New York Society of Addiction Medicine (NYSAM) Annual Conference in New York, clinicians and policymakers focused on integrating evolving policy with patient-centered addiction care.
At the 2026 New York Society of Addiction Medicine (NYSAM) Annual Conference in New York, clinicians and policymakers focused on integrating evolving policy with patient-centered addiction care.
At the 2026 New York Society of...
03/17/2026
Psych Congress Network
Evguenia Makovkina, MD
Conference Coverage
Education Intervention Boosts Psychiatrists’ Knowledge and Attitudes on mOUD
03/07/2026
Evguenia Makovkina, MD
Evguenia Makovkina, MD, discusses key findings from her pilot study examining psychiatrists’ baseline knowledge, attitudes, and prescribing practices related to medications for opioid use disorder (mOUD).
Evguenia Makovkina, MD, discusses key findings from her pilot study examining psychiatrists’ baseline knowledge, attitudes, and prescribing practices related to medications for opioid use disorder (mOUD).
Evguenia Makovkina, MD,...
03/07/2026
Psych Congress Network
a man smoking and drinking
News
Psychological Interventions Offer Minimal Impact in Schizophrenia With SUD
02/05/2026
Maria Mantas
A large systematic review and meta-analysis found psychological and psychosocial interventions had minimal impact in individuals with co-occurring schizophrenia and substance use disorder (SUD).
A large systematic review and meta-analysis found psychological and psychosocial interventions had minimal impact in individuals with co-occurring schizophrenia and substance use disorder (SUD).
A large systematic review and...
02/05/2026
Psych Congress Network
a person breaks a cigarette in half
News
GLP-1 Agonists Show Promise in Treating Alcohol and Substance Use Disorders
11/13/2025
Brionna Mendoza
A review published in the Journal of the Endocrine Society highlights the emerging potential of GLP-1 receptor agonists (GLP-1RAs) as pharmacotherapies for alcohol and substance use disorders (ASUDs).
A review published in the Journal of the Endocrine Society highlights the emerging potential of GLP-1 receptor agonists (GLP-1RAs) as pharmacotherapies for alcohol and substance use disorders (ASUDs).
A review published in the...
11/13/2025
Psych Congress Network
woman surrounded by spilled pills
News
Heart Rate Variability Biofeedback May Reduce Craving and Substance Use During SUD Recovery
10/09/2025
Maria Mantas
Second-generation heart rate variability biofeedback (HRVB) reduced negative affect, craving, and substance use in individuals in early recovery from severe substance use disorder (SUD), according to phase 2 trial results.
Second-generation heart rate variability biofeedback (HRVB) reduced negative affect, craving, and substance use in individuals in early recovery from severe substance use disorder (SUD), according to phase 2 trial results.
Second-generation heart rate...
10/09/2025
Psych Congress Network
tipped over pill bottle with white pills spilling out
News
Fewer Than Half of Medicaid Managed Care Plans Cover All Medications For AUD
04/22/2025
Maria Mantas
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid...
04/22/2025
Psych Congress Network
Woman sitting at bar holding a drink.
News
Semaglutide Reduces Cravings in Adults with Alcohol Use Disorder
03/13/2025
Jolynn Tumolo
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose...
03/13/2025
Psych Congress Network
a cartoon illustration of a man sitting on the floor with this hand on his head, looking distressed.
News
More Than a Fifth of Overdose Decedents Had Non–Substance Mental Health Disorder
09/23/2024
Jolynn Tumolo
In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.
In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.
In 2022, 1 in 5 overdose deaths...
09/23/2024
Psych Congress Network
Mark Garofoli
Q&As
A Closer Look at the Updated CDC Opioid Guideline
09/08/2024
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key...
09/08/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
Ken J. Martz, PsyD, MBA.
Q&As
Tapping Into Neuroplasticity to Power Addiction Recovery
09/06/2024
Kenneth J. Martz, PsyD, MBA, discusses how neuroplasticity can amplify traditional recovery techniques.
Kenneth J. Martz, PsyD, MBA, discusses how neuroplasticity can amplify traditional recovery techniques.
Kenneth J. Martz, PsyD, MBA,...
09/06/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
A person sits holding a pill in one hand and a glass of water in the other
News
Most US Residents Unaware PCPs Can Prescribe Medication for Opioid Use Disorder
08/19/2024
Jolynn Tumolo
Three-quarters of US residents in a national survey did not know primary care physicians (PCPs) could prescribe medications for people with opioid use disorder (OUD) or believed incorrectly that they could not, according to a study findings...
Three-quarters of US residents in a national survey did not know primary care physicians (PCPs) could prescribe medications for people with opioid use disorder (OUD) or believed incorrectly that they could not, according to a study findings...
Three-quarters of US residents...
08/19/2024
Psych Congress Network

More News & Updates

a man smoking and drinking
News
Psychological Interventions Offer Minimal Impact in Schizophrenia With SUD
02/05/2026
Maria Mantas
A large systematic review and meta-analysis found psychological and psychosocial interventions had minimal impact in individuals with co-occurring schizophrenia and substance use disorder (SUD).
A large systematic review and meta-analysis found psychological and psychosocial interventions had minimal impact in individuals with co-occurring schizophrenia and substance use disorder (SUD).
A large systematic review and...
02/05/2026
Psych Congress Network
a person breaks a cigarette in half
News
GLP-1 Agonists Show Promise in Treating Alcohol and Substance Use Disorders
11/13/2025
Brionna Mendoza
A review published in the Journal of the Endocrine Society highlights the emerging potential of GLP-1 receptor agonists (GLP-1RAs) as pharmacotherapies for alcohol and substance use disorders (ASUDs).
A review published in the Journal of the Endocrine Society highlights the emerging potential of GLP-1 receptor agonists (GLP-1RAs) as pharmacotherapies for alcohol and substance use disorders (ASUDs).
A review published in the...
11/13/2025
Psych Congress Network
woman surrounded by spilled pills
News
Heart Rate Variability Biofeedback May Reduce Craving and Substance Use During SUD Recovery
10/09/2025
Maria Mantas
Second-generation heart rate variability biofeedback (HRVB) reduced negative affect, craving, and substance use in individuals in early recovery from severe substance use disorder (SUD), according to phase 2 trial results.
Second-generation heart rate variability biofeedback (HRVB) reduced negative affect, craving, and substance use in individuals in early recovery from severe substance use disorder (SUD), according to phase 2 trial results.
Second-generation heart rate...
10/09/2025
Psych Congress Network
tipped over pill bottle with white pills spilling out
News
Fewer Than Half of Medicaid Managed Care Plans Cover All Medications For AUD
04/22/2025
Maria Mantas
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid...
04/22/2025
Psych Congress Network
Woman sitting at bar holding a drink.
News
Semaglutide Reduces Cravings in Adults with Alcohol Use Disorder
03/13/2025
Jolynn Tumolo
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose...
03/13/2025
Psych Congress Network
a cartoon illustration of a man sitting on the floor with this hand on his head, looking distressed.
News
More Than a Fifth of Overdose Decedents Had Non–Substance Mental Health Disorder
09/23/2024
Jolynn Tumolo
In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.
In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.
In 2022, 1 in 5 overdose deaths...
09/23/2024
Psych Congress Network
Mark Garofoli
Q&As
A Closer Look at the Updated CDC Opioid Guideline
09/08/2024
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key...
09/08/2024
Psychiatry & Behavioral Health
Ken J. Martz, PsyD, MBA.
Q&As
Tapping Into Neuroplasticity to Power Addiction Recovery
09/06/2024
Kenneth J. Martz, PsyD, MBA, discusses how neuroplasticity can amplify traditional recovery techniques.
Kenneth J. Martz, PsyD, MBA, discusses how neuroplasticity can amplify traditional recovery techniques.
Kenneth J. Martz, PsyD, MBA,...
09/06/2024
Psychiatry & Behavioral Health
A person sits holding a pill in one hand and a glass of water in the other
News
Most US Residents Unaware PCPs Can Prescribe Medication for Opioid Use Disorder
08/19/2024
Jolynn Tumolo
Three-quarters of US residents in a national survey did not know primary care physicians (PCPs) could prescribe medications for people with opioid use disorder (OUD) or believed incorrectly that they could not, according to a study findings...
Three-quarters of US residents in a national survey did not know primary care physicians (PCPs) could prescribe medications for people with opioid use disorder (OUD) or believed incorrectly that they could not, according to a study findings...
Three-quarters of US residents...
08/19/2024
Psych Congress Network
Three illustrated faces, one sad, one neutral, one happy, with a human hand picking up the happy face
News
Buprenorphine an Effective Treatment for OUD With Fentanyl Use
08/09/2024
Brionna Mendoza
Buprenorphine, whether administered sublingually or subcutaneously, appears to be an effective option for the treatment of opioid use disorder (OUD) with fentanyl use.
Buprenorphine, whether administered sublingually or subcutaneously, appears to be an effective option for the treatment of opioid use disorder (OUD) with fentanyl use.
Buprenorphine, whether...
08/09/2024
Psych Congress Network
Brooke Kempf, PMHNP-BC
Videos
Navigating Anxiety, Pain, and Mixed Features in Depressive Disorders
04/16/2026
Brooke Kempf, MSN, PMHNP-BC
Psych Congress Steering Committee member Brooke Kempf, PMHNP-BC, offers clinicians a practical framework for differentiating overlapping symptoms, anxious distress, and mixed features in MDD.
Psych Congress Steering Committee member Brooke Kempf, PMHNP-BC, offers clinicians a practical framework for differentiating overlapping symptoms, anxious distress, and mixed features in MDD.
Psych Congress Steering...
04/16/2026
Psych Congress Network
A doctor sits at a table holding a pill bottle in one hand while filling out paperwork
News
Algorithm-Guided Treatment Improves Outcomes in Major Depressive Disorder
04/14/2026
Brionna Mendoza
A systematic review published in Frontiers in Psychiatry reports that algorithm-guided treatment (AGT) is generally associated with improved remission rates and more timely treatment modifications compared with treatment as usual (TAU).
A systematic review published in Frontiers in Psychiatry reports that algorithm-guided treatment (AGT) is generally associated with improved remission rates and more timely treatment modifications compared with treatment as usual (TAU).
A systematic review published in...
04/14/2026
Psych Congress Network
a person attempts to pick up a glass of water
News
Valbenazine Demonstrates Higher Persistence vs Deutetrabenazine in TD Patients
04/14/2026
Maria Mantas
Neurocrine Biosciences reported new real-world evidence demonstrating higher treatment persistence with valbenazine (Ingrezza) compared with deutetrabenazine (Austedo XR) among adults with tardive dyskinesia (TD).
Neurocrine Biosciences reported new real-world evidence demonstrating higher treatment persistence with valbenazine (Ingrezza) compared with deutetrabenazine (Austedo XR) among adults with tardive dyskinesia (TD).
Neurocrine Biosciences reported...
04/14/2026
Psych Congress Network
A boy's hand holding a pill that says ADHD
News
Open-Label Extension Trial Supports Long-Term Use of Viloxazine ER in Children and Adolescents
04/13/2026
A phase 3 open-label extension trial found viloxazine ER to be safe and effective for the long-term treatment of pediatric ADHD.
A phase 3 open-label extension trial found viloxazine ER to be safe and effective for the long-term treatment of pediatric ADHD.
A phase 3 open-label extension...
04/13/2026
Psych Congress Network
A teddy bear against a blue background wearing a mask and stethoscope.
News

ADHD Incidence Trends Accelerated After DSM-5 Changes and COVID-19 Disruptions
04/10/2026
Brionna Mendoza
Attention-deficit/hyperactivity disorder (ADHD) diagnosis rates in people younger than 30 years in British Columbia, Canada, rose steadily from 2003 to 2023 and appeared to accelerate after both DSM-5 implementation and the COVID-19 pandemic.
Attention-deficit/hyperactivity disorder (ADHD) diagnosis rates in people younger than 30 years in British Columbia, Canada, rose steadily from 2003 to 2023 and appeared to accelerate after both DSM-5 implementation and the COVID-19 pandemic.
Attention-deficit/hyperactivity...
04/10/2026
Psych Congress Network
Philip Gehrman, PhD, CBSM, FAASM
Videos
Targeting Sleep to Improve Mental Health Outcomes
04/08/2026
Philip Gehrman, PhD
Psych Congress Steering Committee Partner Philip Gehrman, PhD, CBSM, FAASM, discusses how targeting sleep may improve outcomes for patients with co-occurring sleep and psychiatric disorders.
Psych Congress Steering Committee Partner Philip Gehrman, PhD, CBSM, FAASM, discusses how targeting sleep may improve outcomes for patients with co-occurring sleep and psychiatric disorders.
Psych Congress Steering...
04/08/2026
Psych Congress Network
A profile of a person split in half, one half teal and the other purple, with a swirl line over the head
News
Higher Risk of Premature Death Found in Bipolar II Disorder
04/07/2026
Brionna Mendoza
Bipolar II disorder (BD-II) is associated with significantly increased mortality, according to a large population-based cohort study published in JAMA Network Open.
Bipolar II disorder (BD-II) is associated with significantly increased mortality, according to a large population-based cohort study published in JAMA Network Open.
Bipolar II disorder (BD-II) is...
04/07/2026
Psych Congress Network
a man with depression looks out a window major depressive disorder
News
Psilocybin Produces Mixed Outcomes in Phase 2b MDD Study
04/01/2026
Brionna Mendoza
A Phase 2b randomized clinical trial published in JAMA Psychiatry found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive...
A Phase 2b randomized clinical trial published in JAMA Psychiatry found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive...
A Phase 2b randomized clinical...
04/01/2026
Psych Congress Network
spilled bottle of white pills
News
Tazbentetol Demonstrates Early Symptom Improvement in Phase 2 Schizophrenia Trial
04/01/2026
Maria Mantas
Interim results from a phase 2 randomized, double-blind, placebo-controlled trial of tazbentetol demonstrated early signals of efficacy across schizophrenia symptom domains.
Interim results from a phase 2 randomized, double-blind, placebo-controlled trial of tazbentetol demonstrated early signals of efficacy across schizophrenia symptom domains.
Interim results from a phase 2...
04/01/2026
Psych Congress Network
Timothy Wilens, MD
Videos
Clinical Patterns of ADHD Comorbidities Across the Lifespan
04/01/2026
Timothy Wilens, MD
Timothy Wilens, MD, explores common patterns of attention-deficit/hyperactivity disorder (ADHD) psychiatric comorbidities throughout different developmental stages.
Timothy Wilens, MD, explores common patterns of attention-deficit/hyperactivity disorder (ADHD) psychiatric comorbidities throughout different developmental stages.
Timothy Wilens, MD, explores...
04/01/2026
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use